Focus Advisor Solutions LLC Purchases 3,422 Shares of Medpace Holdings, Inc. $MEDP

Focus Advisor Solutions LLC increased its position in Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 107.5% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 6,604 shares of the company’s stock after acquiring an additional 3,422 shares during the period. Focus Advisor Solutions LLC’s holdings in Medpace were worth $4,122,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of MEDP. Johnson Financial Group Inc. acquired a new position in Medpace during the 2nd quarter valued at about $27,000. Jones Financial Companies Lllp bought a new position in Medpace in the 2nd quarter worth about $30,000. Allied Private Wealth LLC bought a new position in Medpace in the 2nd quarter worth about $31,000. Kilter Group LLC acquired a new stake in shares of Medpace in the second quarter valued at approximately $31,000. Finally, Gen Wealth Partners Inc acquired a new stake in shares of Medpace in the third quarter valued at approximately $38,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on MEDP. Royal Bank Of Canada lifted their price target on Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a report on Friday, July 24th. Mizuho set a $730.00 price objective on Medpace in a report on Friday, October 23rd. Robert W. Baird set a $699.00 target price on Medpace in a research report on Friday, October 23rd. TD Cowen raised their target price on Medpace from $492.00 to $673.00 and gave the company a “hold” rating in a research report on Friday, October 23rd. Finally, Weiss Ratings raised Medpace from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, October 8th. Three equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $649.27.

Read Our Latest Research Report on MEDP

Medpace Price Performance

NASDAQ MEDP opened at $609.38 on Friday. Medpace Holdings, Inc. has a 12 month low of $373.00 and a 12 month high of $693.97. The company has a market capitalization of $17.04 billion, a P/E ratio of 35.93, a PEG ratio of 2.52 and a beta of 1.12. The company’s 50 day simple moving average is $634.56 and its 200 day simple moving average is $535.10.

Medpace (NASDAQ:MEDP – Get Free Report) last issued its earnings results on Wednesday, October 21st. The company reported $4.84 earnings per share for the quarter, topping analysts’ consensus estimates of $4.44 by $0.40. The firm had revenue of $716.00 million during the quarter, compared to analysts’ expectations of $714.47 million. Medpace had a net margin of 18.24% and a return on equity of 99.76%. The firm’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same period last year, the firm posted $3.86 earnings per share. On average, analysts anticipate that Medpace Holdings, Inc. will post 18.06 earnings per share for the current year.

Insider Activity

In related news, CEO August J. Troendle sold 21,966 shares of Medpace stock in a transaction on Wednesday, September 30th. The stock was sold at an average price of $625.47, for a total value of $13,739,074.02. Following the transaction, the chief executive officer directly owned 338,225 shares in the company, valued at $211,549,590.75. The trade was a 6.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, General Counsel Stephen P. Ewald sold 1,245 shares of the business’s stock in a transaction on Thursday, October 29th. The stock was sold at an average price of $690.00, for a total value of $859,050.00. Following the sale, the general counsel directly owned 19,098 shares in the company, valued at $13,177,620. This trade represents a 6.12% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 234,078 shares of company stock worth $147,170,305. Insiders own 20.50% of the company’s stock.

Medpace Profile

(Free Report)

Medpace Holdings, Inc. is a global contract research organization (CRO) that provides clinical development services to the biotechnology, pharmaceutical and medical device industries. Founded in 1992 and headquartered in Cincinnati, Ohio, the company works with clients developing treatments and medical products across a range of therapeutic areas. Medpace offers services spanning the clinical development process, including clinical trial planning and management, regulatory affairs, clinical laboratory testing, data management, biostatistics, medical writing and pharmacovigilance.

Featured Stories

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report).

Institutional Ownership by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.